BioCentury | Feb 19, 2021
Politics, Policy & Law

Study could revive pressure for FDA to release refuse-to-file, complete response letters

...FDA’s advice. The analysis of NDAs and efficacy supplements filed between Jan. 1, 2008, and Dec...
BioCentury | Feb 16, 2021
Deals

Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford

...$15 million in Cytovia equity or in upfront cash if certain conditions aren’t met by Dec...
BioCentury | Feb 3, 2021
Product Development

Sputnik V on par with other COVID-19 vaccines before and after boost

...the reported efficacy for the Russian vaccine was based on COVID-19 cases that occurred before Dec...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...of therapies for orphan and inflammatory disorders.Horizon had more than $2 billion in cash at Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Autophagy-activating gene therapy to treat recurrent HSV-2 infection

...STATUS: Patent and licensing status unavailablePUBLICATION DETAILS: Hait, A. et al. Sci. Immunol.; published online Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Small molecule epoxide hydrolase inhibitor for Alzheimer’s

...available for licensing or partneringPUBLICATION DETAILS: Ghosh, A. et al. Sci. Transl. Med.; published online Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Epigenetic repressors of repetitive elements as cancer targets

...culture; miceLICENSING STATUS: Unpatented; available for partneringPUBLICATION DETAILS: Shen, J. et al. Cell; published online Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting histone trimethylation to treat Alzheimer’s

...STATUS: Patent and licensing status unavailablePUBLICATION DETAILS: Cao, Q. et al. Sci. Adv.; published online Dec...
BioCentury | Jan 26, 2021
Politics, Policy & Law

EU transparency scheme raises concerns over potential COVID-19 vaccine export restrictions

...conditional approval for the AZ vaccine on Friday. The U.K., which authorized the AZ vaccine on Dec...
BioCentury | Jan 24, 2021
Regulation

Lupus nephritis patients gain oral option as FDA approves Aurinia’s Lupkynis

...some additional incumbency beyond a narrow first-mover advantage spanning about five weeks since that drug’s Dec...
Items per page:
1 - 10 of 12562
BioCentury | Feb 19, 2021
Politics, Policy & Law

Study could revive pressure for FDA to release refuse-to-file, complete response letters

...FDA’s advice. The analysis of NDAs and efficacy supplements filed between Jan. 1, 2008, and Dec...
BioCentury | Feb 16, 2021
Deals

Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford

...$15 million in Cytovia equity or in upfront cash if certain conditions aren’t met by Dec...
BioCentury | Feb 3, 2021
Product Development

Sputnik V on par with other COVID-19 vaccines before and after boost

...the reported efficacy for the Russian vaccine was based on COVID-19 cases that occurred before Dec...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...of therapies for orphan and inflammatory disorders.Horizon had more than $2 billion in cash at Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Autophagy-activating gene therapy to treat recurrent HSV-2 infection

...STATUS: Patent and licensing status unavailablePUBLICATION DETAILS: Hait, A. et al. Sci. Immunol.; published online Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Small molecule epoxide hydrolase inhibitor for Alzheimer’s

...available for licensing or partneringPUBLICATION DETAILS: Ghosh, A. et al. Sci. Transl. Med.; published online Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Epigenetic repressors of repetitive elements as cancer targets

...culture; miceLICENSING STATUS: Unpatented; available for partneringPUBLICATION DETAILS: Shen, J. et al. Cell; published online Dec...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting histone trimethylation to treat Alzheimer’s

...STATUS: Patent and licensing status unavailablePUBLICATION DETAILS: Cao, Q. et al. Sci. Adv.; published online Dec...
BioCentury | Jan 26, 2021
Politics, Policy & Law

EU transparency scheme raises concerns over potential COVID-19 vaccine export restrictions

...conditional approval for the AZ vaccine on Friday. The U.K., which authorized the AZ vaccine on Dec...
BioCentury | Jan 24, 2021
Regulation

Lupus nephritis patients gain oral option as FDA approves Aurinia’s Lupkynis

...some additional incumbency beyond a narrow first-mover advantage spanning about five weeks since that drug’s Dec...
Items per page:
1 - 10 of 12562